• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Oncology/Infection
  • A methodology study to support the future investigation of AZD2171 in patients with Acute Myeloid Leukaemia (AML)

Disease
colorectal cancer
Drug Name
RECENTIN
Generic Name
AZD2171
Sponsor
AstraZeneca
Drug Status
In Development
Phase
I
Start Date
Mar 22, 2004
Study Name
D8480M00001
Study Id
D8480M00001
Recruiting Status
Closed
Protocol Status
Not Available
Report Status
Not Available

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013